Acorn International Trading
Recent News About Acorn International Trading
-
Wadhwa: 'The SEC will continue to vigorously enforce the books and records provisions of the federal securities laws'
Citigroup Global Markets Inc. (CGMI) is facing charges from the Securities and Exchange Commission (SEC) for recordkeeping failures concerning underwriting expenses, according to a press release. The SEC revealed resolved cease-and-desist actions against this broker-dealer.
-
Liu: 'Today’s proposed resolution sends a clear signal that the FTC and its state partners will scrutinize pharmaceutical mergers that enable such practices'
Amgen, the biopharmaceutical giant, is set to resolve FTC and state concerns regarding its acquisition of Horizon Therapeutics, according to a press release. The settlement terms will prevent Amgen from using its drug portfolio to unfairly compete with rivals and will mandate pre-approval for related product acquisitions.
-
Tai: 'The government of Mexico has been an outstanding partner' in settling workers' rights abuses
The United States and Mexico have announced remediation plans to address a denial-of-rights case at a Mexico facility of Spain-based manufacturer Draxton, the Office of the U.S. Trade Representative.
-
Grewal: SEC alleges Florida man 'is a serial insider trader whose conduct merits the stiffest penalties available to the Commission'
An investment advisor based in Wellington, Fla. has been charged with insider trading by the Securities and Exchange Commission.
-
Vedova: 'The proposed order is a victory in creating a fair and competitive playing field in the e-prescription drug market'
The Federal Trade Commission reached a proposed settlement with Surescripts in an illegal monopolization case that aims to address anticompetitive actions resulting in increased prices, hindered innovation and limited customer choices in the e-prescription market.
-
Werner: 'This action seeks to protect the investing public and hold Heart accountable for his actions'
The U.S. Securities and Exchange Commission charged Richard Heart, the founder of Hex, with the misappropriation of millions from investor funds raised through unregistered crypto asset securities offerings, which garnered more than $1 billion.
-
Grewal: 'DWAC failed to disclose its discussions with TMTG'
On July 20, the U.S. Securities and Exchange Commission announced charges against Digital World Acquisition Corporation (DWAC), a special purpose acquisition company (SPAC), for material misrepresentation to investors.
-
Gensler: 'I thank Natasha and Keith for stepping in on an interim basis to lead the Division of Examinations'
The U.S. Securities and Exchange Commission recently appointed Natasha Vij Greiner and Keith E. Cassidy as interim acting co-directors of the Division of Examinations, effective immediately.
-
Gensler: 'We live in an historic, transformational age with regard to predictive data analytics and the use of artificial intelligence'
The Securities and Exchange Commission proposed requiring broker-dealers and investment advisers to address possible conflicts of interest related to the use of predictive data analytics and similar technologies.
-
Apps: 'The SEC remains committed to holding accountable those who prey upon innocent investors'
The Securities and Exchange Commission recently issued a release regarding charges brought against Eliyahu Weinstein, a twice-convicted fraudster from Lakewood, N.J., and five other individuals for their involvement in a $38 million Ponzi-like scheme aimed at defrauding investors.
-
Vedova: 'It’s critical that the market for health care product advertising remains competitive'
The Federal Trade Commission recently initiated legal action in order to block IQVIA's acquisition of Propel Media, with the goal of preventing a significant increase in market concentration within the healthcare programmatic advertising industry.
-
SEC accuses ex-Pfizer employee Dagar of using Pfizer trial information 'to enrich himself and his friend'
The U.S. Securities and Exchange Commission (SEC) has announced that it filed insider trading charges against ex-Pfizer employee Amit Dagar and his business partner, Atul Bhiwapurkar, for trading before the announcement of a successful trial of the antiviral COVID-19 treatment Paxlovid,